StockData

Cardiff Oncology vs Onconetix

CRDF and ONCO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CRDF and ONCO compare

Cardiff Oncology is the larger company, worth 5.2 times as much as Onconetix ($65.3M against $12.4M).

Cardiff Oncology grew revenue faster over the last twelve months (−7.0% versus −51.3% for Onconetix).

Onconetix keeps more of each dollar of sales as profit, with a net margin of −1579% compared with −7884% at Cardiff Oncology.

Cardiff Oncology scores higher on the StockData Score (7 against 3 for Onconetix), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCRDFONCO
Size and price
Market cap$65.3M$12.4M
Share price$0.839$3.15
Change, 1 year−59.3%−99.7%
Change, 5 years−85.0%−100.0%
Beta (5Y)1.584.81
Employees3112
StockData Score
Total score7 (better)3
Valuation score01 (better)
Growth score11
Performance score1 (better)0
Health score5 (better)1
Dividend score00
Valuation
P/S128×19.3× (better)
P/B2.5×0.9× (better)
Growth
Revenue growth (TTM)−7.0% (better)−51.3%
Revenue growth, 5Y average10.1%–
Profitability
Gross margin–80.4%
Operating margin−8320%−2525% (better)
Net margin−7884%−1579% (better)
Return on equity−94.1% (better)−105%
Return on invested capital–−196%
Financial health
Debt / equity0.00–
Interest coverage–−52.4×
Current ratio3.30 (better)2.21
Altman Z-score−16.24−12.24 (better)
Piotroski F-score16 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions24.2%1.7%
Held by insiders4.9%40.3%
Insider net buying, 12 months$1.1M (better)$8.4K
Short interest, % of float16.6%40.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.